Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer

Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer

Background Immunotherapy has revolutionized therapeutic patterns of small cell lung cancer (SCLC). Human leukocyte antigen class II (HLA class II) is related to antitumor immunity. However, the implications of HLA class II in SCLC remain incompletely understood.Materials and methods We investigated...

Full description

Bibliographic Details
Main Authors: Jun Zhu, Hao Wang, Wei Li, Wei Zhang, Liping Zhang, Caicun Zhou, Peixin Chen, Chenglong Sun, Chunyan Wu, Yayi He, Jia Yu, Lishu Zhao, Sha Zhao
Format: Article
Language:English
Published: BMJ Publishing Group 2021-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/8/e002554.full

Internet

https://jitc.bmj.com/content/9/8/e002554.full

Similar Items